Fatty Liver or NASH: The Future of Noninvasive Diagnosis and Assessment
Host: Ira M. Jacobson, MD
\n\n Guest: Zobair M Younossi MD, MPH, FACP, FACG, AGAF, FAASLD
\n\n Guest: Aaron Z. Tokayer, MD
\n\n\n \n
The use of noninvasive tools in NAFLD/NASH has become more prevalent over the last several years, with increased availability of imaging and serum-based tools. A forum of experts convened to discuss optimal use of these tools in NAFLD/NASH using a series of clinical assertion statements. These statements covered screening patients with diabetes, applicability of liver enzymes in determining fibrosis stage, use of transient elastography and blood-based tools, such as the Enhanced Liver Fibrosis test, and potential genetic testing. Here, Drs Jacobson and Younossi summarize the research and discussion points from the forum.